Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Make a Dazzling Site in 5 Basic Advances - 2NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- 3Amid Iran war, 53 of Israel's future scientists showcase projects in Jerusalem contest
- 4Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- 5Whale stranded off Germany for days free again
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Find the Captivating Professional flowerbeds of the US
- Pick Your #1 game to observe
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- A Manual for Extravagant Vehicles Available in 2024
- Manual for Instructive Application for Youngsters
- Malaysia To Revive Search for Missing Flight MH370
- If someone's always late, is it time blindness, or are they just being rude?
- Private sector revives the climate disaster database Trump tried to squash
